Zevra Therapeutics ZVRA 深 沪
已收盘 10-09 16:00:00 美东时间
11.39
+0.390
+3.55%
华盛通- 最 高11.46
- 今 开10.95
- 成交量 73.07万股
- 最 低 10.95
- 昨 收 11.00
- 总市值 6.76亿
- 52周最高 15.035
- 市盈率 静 8.41
- 换手率 1.23%
- 52周最低 8.01
- 委 比 9.88%
- 总股本 5938.38万
- 历史最高 418.40
- 量 比 0.74
- 振 幅 4.64%
- 历史最低 0.206
- 每 手 1
- 风险率 1.56%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 450 points on Thursday. Shares of argenx SE – ADR (NASDAQ:ARGX) fell sharply in pre-market trading after the company announced plans to discontinue Phase 3 UNITY study of efgartigimod subcutaneous in adults with moderate...
10-08 20:07
MongoDB, Credo Technology Group And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. stock futures were lower this morning, with the Nasdaq 100 futures falling around 0.3% on Wednesday. Shares of Mongodb Inc (NASDAQ:MDB) fell sharply in pre-market trading following second-quarter results. MongoDB reported quarterly earnings of $1.90 per share, which beat the Street estimate of ...
09-02 20:03
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Zevra Therapeutics granted stock options to four new employees under its 2023 Employment Inducement Award Plan. The options, totaling 92,200 shares, vest over four years, with 25% vesting on the first anniversary of employment and the rest vesting in equal annual installments. The company, focused on rare disease therapies, has successfully commercialized a treatment for Niemann-Pick disease type C.
08-21 20:30
美股大行评级 | 塔吉特获13家大行上调目标价；Moderna携手默沙东齐获大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持Ultragenyx Pharmaceutical"超配"评级，目标价从96美元升至103美元；Canaccord Genuity：维持Ultragenyx Pharmaceutical"买入"评级，目标价从81美元升至83美元
08-21 11:40
HC Wainwright & Co. Reiterates Buy on Zevra Therapeutics, Maintains $26 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and maintains $26 price target.
08-20 18:24
美股大行评级 | 花旗、富国下调闪迪目标价，低至1400美元；百济神州、多邻国、DoorDash、Shopify等获多家机构上调评级
今日重点评级关注：康托·菲茨杰拉德：维持EyePoint"超配"评级，目标价从47美元升至55美元；伯恩斯坦：维持Figure Technology"跑赢大市"评级，目标价从67美元升至70美元
08-07 13:41
Zevra Therapeutics Q2 EPS $0.14 Beats $0.11 Estimate, Sales $39.663M Beat $33.881M Estimate
Zevra Therapeutics (NASDAQ:ZVRA) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.11 by 27.27 percent. This is a 88.71 percent decrease over earnings of $1.24 per share from the same period last year. The company reported quarterly sales of $39.663 milli...
08-06 04:23
Zevra Therapeutics Announces Publication Of "Long-Term Real-World Safety And Effectiveness Of Arimoclomol In Individuals With NPC: Outcomes From US Early Access Program Over A 4-Year Period" In Molecular Genetics And Metabolism
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced the publication of "Long-term real-world safety and effectiveness of arimoclomol in individuals with NPC: Out...
08-03 19:34
美股大行评级 | ITG、Bending Spoons获多家大行首予买入评级；瑞银下调微软目标价从510美元降至480美元
今日重点评级关注：BTIG：上调Outlook Therapeutics"买入"评级，目标价4美元；TD Cowen：维持Nakamoto"买入"评级，目标价从1美元升至17美元
07-28 11:34
Zevra Therapeutics Stock Down — European Panel Slams Arimoclomol Bid for Niemann-Pick Type C
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) shares are trading lower on Friday as the company faces challenges following a negative opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) regarding its Marketing Authorization Application for arimoclomol for Niem...
07-25 00:47
